151 related articles for article (PubMed ID: 36370891)
1. Total cost of care associated with opioid use disorder treatment.
Toseef MU; Durfee J; Podewils LJ; Blum J; McEwen D; Hanratty R; Everhart R
Prev Med; 2023 Jan; 166():107345. PubMed ID: 36370891
[TBL] [Abstract][Full Text] [Related]
2. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
[TBL] [Abstract][Full Text] [Related]
3. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
[TBL] [Abstract][Full Text] [Related]
4. The cost of opioid use disorder-related conditions in Medicare.
Mark TL; Parish WJ; Weber EM; Steinberg DG; Henretty K
Drug Alcohol Depend; 2023 Mar; 244():109778. PubMed ID: 36701935
[TBL] [Abstract][Full Text] [Related]
5. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
6. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
7. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
[TBL] [Abstract][Full Text] [Related]
8. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
9. Initiation and Receipt of Medication for Opioid Use Disorder Among Adolescents and Young Adults in 4 State Medicaid Programs in 2018: Improving Medicaid Quality Metrics.
Lynch V; Clemans-Cope L
Subst Use Addctn J; 2024 Jul; 45(3):434-445. PubMed ID: 38294428
[TBL] [Abstract][Full Text] [Related]
10. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
11. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
12. Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
Hollander MAG; Chang CH; Douaihy AB; Hulsey E; Donohue JM
Drug Alcohol Depend; 2021 Oct; 227():108927. PubMed ID: 34358766
[TBL] [Abstract][Full Text] [Related]
13. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
Johnson K; Hills H; Ma J; Brown CH; McGovern M
Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
[No Abstract] [Full Text] [Related]
14. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
16. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
[TBL] [Abstract][Full Text] [Related]
17. Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.
Mahone A; Enich M; Treitler P; Lloyd J; Crystal S
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):606-617. PubMed ID: 37506336
[No Abstract] [Full Text] [Related]
18. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
[TBL] [Abstract][Full Text] [Related]
19. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
[TBL] [Abstract][Full Text] [Related]
20. Outpatient follow-up and use of medications for opioid use disorder after residential treatment among Medicaid enrollees in 10 states.
; Cole ES; Allen L; Austin A; Barnes A; Chang CH; Clark S; Crane D; Cunningham P; Fry CE; Gordon AJ; Hammerslag L; Idala D; Kennedy S; Kim JY; Krishnan S; Lanier P; Mahakalanda S; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Tang L; Zivin K; Donohue JM
Drug Alcohol Depend; 2022 Dec; 241():109670. PubMed ID: 36332591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
